JGC
BDTX icon

J. Goldman & Co’s Black Diamond Therapeutics BDTX Stock Holding History

J. Goldman & Co’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-270,000
Closed -$656K – 676
2025
Q4 		$656K Buy
+270,000
New +$956K 0.02% 437
2025
Q3 		– Sell
-323,999
Closed -$804K – 465
2025
Q2 		$804K Buy
323,999
+67,500
+26% +$130K 0.02% 348
2025
Q1 		$398K Buy
+256,499
New +$538K 0.01% 412

Other funds holding BDTX

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

J. Goldman & Co's BDTX Position: Q1 2026 in Review

J. Goldman & Co sold out of Black Diamond Therapeutics (BDTX) in Q1 2026, closing a stake of 270,000 shares — an estimated $656K sold.

J. Goldman & Co first reported a position in BDTX in Q1 2025 and held it in 3 quarters. The position peaked at $804K in Q2 2025. 104 funds tracked by Wall St. Rank hold BDTX as of Q1 2026.

  • J. Goldman & Co reported no remaining Black Diamond Therapeutics position as of Q1 2026 after selling out during the quarter.
  • J. Goldman & Co sold 270,000 Black Diamond Therapeutics shares in Q1 2026, an estimated $656K.
  • J. Goldman & Co first reported a position in Black Diamond Therapeutics in Q1 2025 and held it in 3 quarters.
  • J. Goldman & Co's Black Diamond Therapeutics position peaked at $804K in Q2 2025.
  • 104 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q1 2026.

Based on J. Goldman & Co's 13F filing for Q1 2026, filed 15 May 2026.